Depression

Midwest CEPAC, New England CEPAC

Major depressive disorder (MDD) is a common and debilitating condition; on an annual basis, it is estimated that nearly 14 million Americans will have at least one episode of MDD.  While definitions of so-called “treatment-resistant” depression vary, this generally refers to patients with persistent depression after attempted management with two or more medications.

Interventions of interest, 2019 review: Esketamine (Janssen)

Interventions of interest, 2011 review: Repetitive transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and cognitive-behavioral therapy/interpersonal therapy

For questions, please contact Ellie Adair, Program Manager, at eadair@icer-review.org.

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
LAX Room
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials


ASSOCIATED MEETING & MATERIALS

New England CEPAC
December 9, 2011 10am-4pm

Brown University, Providence, RI

Key Dates

Associated Materials

12/09/2011

12/09/2011

Public comments received on the Draft Evidence Report.